echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > BMS is working with insitro to develop drugs for ALS

    BMS is working with insitro to develop drugs for ALS

    • Last Update: 2021-03-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    BMS
    signed a five-year cooperation agreement with Machine Learning specialist Intro to develop drugs for the treatment of amyotrophic lateral sclerosis (ALS) and alzheimer's disease.Under the agreement, BMS will make an advance payment of $50 million to Intro, and Insitro will be eligible for an additional $20 million in recent business milestones, as well as
    's further milestones of more than $2 billion
    and sales royalties.Insitro will use its novel platform to develop disease models derived from induced popotent stem cells (iPSCs) for ALS and frontal temporal lobe dementia to identify candidate targets.The platform applies machine learning, human genetics, and functional genomics to generate and optimize in-body predictive models and help identify and develop treatments.
    , BMS will be able to select a number of objectives to advance clinical development and will also be responsible for regulatory submission and ultimately commercial activities."We believe machine learning and data generated by the new experimental platform provides an opportunity to rethink how we discover and design new drugs," said Richard Hargreaves, senior vice president of research and early development at BMS Neuroscience TRC.
    The current medical needs for treatments for ALS and FTD have not been met, and we are excited about the prospect of working with the Insitro team to achieve our common goal of identifying conversion therapies for patients with these devastating diseases." (cyy123.com)original source:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.